285 related articles for article (PubMed ID: 2894945)
1. In vitro evidence against the oxidation of quinidine by the sparteine/debrisoquine monooxygenase of human liver.
Otton SV; Brinn RU; Gram LF
Drug Metab Dispos; 1988; 16(1):15-7. PubMed ID: 2894945
[TBL] [Abstract][Full Text] [Related]
2. Evidence in humans for variant allozymes of the nondeficient sparteine/debrisoquine monooxygenase (P45OIID 1) in vitro.
Tyndale RF; Inaba T; Kalow W
Drug Metab Dispos; 1989; 17(3):334-40. PubMed ID: 2568917
[TBL] [Abstract][Full Text] [Related]
3. Substrate specificity of the form of cytochrome P-450 catalyzing the 4-hydroxylation of debrisoquine in man.
Boobis AR; Murray S; Kahn GC; Robertz GM; Davies DS
Mol Pharmacol; 1983 Mar; 23(2):474-81. PubMed ID: 6220203
[TBL] [Abstract][Full Text] [Related]
4. Use of quinidine inhibition to define the role of the sparteine/debrisoquine cytochrome P450 in metoprolol oxidation by human liver microsomes.
Otton SV; Crewe HK; Lennard MS; Tucker GT; Woods HF
J Pharmacol Exp Ther; 1988 Oct; 247(1):242-7. PubMed ID: 3171974
[TBL] [Abstract][Full Text] [Related]
5. A human cytochrome P-450 characterized by inhibition studies as the sparteine-debrisoquine monooxygenase.
Inaba T; Nakano M; Otton SV; Mahon WA; Kalow W
Can J Physiol Pharmacol; 1984 Jul; 62(7):860-2. PubMed ID: 6498616
[TBL] [Abstract][Full Text] [Related]
6. Enzymatic basis of the debrisoquine/sparteine-type genetic polymorphism of drug oxidation. Characterization of bufuralol 1'-hydroxylation in liver microsomes of in vivo phenotyped carriers of the genetic deficiency.
Dayer P; Kronbach T; Eichelbaum M; Meyer UA
Biochem Pharmacol; 1987 Dec; 36(23):4145-52. PubMed ID: 3689440
[TBL] [Abstract][Full Text] [Related]
7. Involvement of the cytochrome P-450IID subfamily in minaprine 4-hydroxylation by human hepatic microsomes.
Marre F; Fabre G; Lacarelle B; Bourrie M; Catalin J; Berger Y; Rahmani R; Cano JP
Drug Metab Dispos; 1992; 20(2):316-21. PubMed ID: 1352227
[TBL] [Abstract][Full Text] [Related]
8. Relationship between oxidative metabolism of 2-acetylaminofluorene, debrisoquine, bufuralol, and aldrin in human liver microsomes.
McManus ME; Boobis AR; Minchin RF; Schwartz DM; Murray S; Davies DS; Thorgeirsson SS
Cancer Res; 1984 Dec; 44(12 Pt 1):5692-7. PubMed ID: 6498831
[TBL] [Abstract][Full Text] [Related]
9. Bufuralol hydroxylation by cytochrome P450 2D6 and 1A2 enzymes in human liver microsomes.
Yamazaki H; Guo Z; Persmark M; Mimura M; Inoue K; Guengerich FP; Shimada T
Mol Pharmacol; 1994 Sep; 46(3):568-77. PubMed ID: 7935340
[TBL] [Abstract][Full Text] [Related]
10. Oxidation of quinidine by human liver cytochrome P-450.
Guengerich FP; Müller-Enoch D; Blair IA
Mol Pharmacol; 1986 Sep; 30(3):287-95. PubMed ID: 3748010
[TBL] [Abstract][Full Text] [Related]
11. Substrate specificity of human liver cytochrome P-450 debrisoquine 4-hydroxylase probed using immunochemical inhibition and chemical modeling.
Wolff T; Distlerath LM; Worthington MT; Groopman JD; Hammons GJ; Kadlubar FF; Prough RA; Martin MV; Guengerich FP
Cancer Res; 1985 May; 45(5):2116-22. PubMed ID: 3921236
[TBL] [Abstract][Full Text] [Related]
12. Debrisoquine/sparteine-type polymorphism of drug oxidation. Purification and characterization of two functionally different human liver cytochrome P-450 isozymes involved in impaired hydroxylation of the prototype substrate bufuralol.
Gut J; Catin T; Dayer P; Kronbach T; Zanger U; Meyer UA
J Biol Chem; 1986 Sep; 261(25):11734-43. PubMed ID: 3745165
[TBL] [Abstract][Full Text] [Related]
13. Hepatic monooxygenase activities in subjects with a genetic defect in drug oxidation.
Meier PJ; Mueller HK; Dick B; Meyer UA
Gastroenterology; 1983 Sep; 85(3):682-92. PubMed ID: 6603386
[TBL] [Abstract][Full Text] [Related]
14. Polymorphic oxidation of debrisoquine and sparteine.
Eichelbaum M
Prog Clin Biol Res; 1986; 214():157-67. PubMed ID: 3523506
[No Abstract] [Full Text] [Related]
15. Mechanism of cytochrome P450 2D6-catalyzed sparteine metabolism in humans.
Ebner T; Meese CO; Eichelbaum M
Mol Pharmacol; 1995 Dec; 48(6):1078-86. PubMed ID: 8848008
[TBL] [Abstract][Full Text] [Related]
16. Quinidine and the identification of drugs whose elimination is impaired in subjects classified as poor metabolizers of debrisoquine.
Speirs CJ; Murray S; Boobis AR; Seddon CE; Davies DS
Br J Clin Pharmacol; 1986 Dec; 22(6):739-43. PubMed ID: 3567021
[TBL] [Abstract][Full Text] [Related]
17. Interactions of bupranolol with the polymorphic debrisoquine/sparteine monooxygenase (CYP2D6).
Pressacco J; Muller R; Kalow W
Eur J Clin Pharmacol; 1993; 45(3):261-4. PubMed ID: 8276051
[TBL] [Abstract][Full Text] [Related]
18. Involvement of CYP2D6 in oxidative metabolism of cinnarizine and flunarizine in human liver microsomes.
Narimatsu S; Kariya S; Isozaki S; Ohmori S; Kitada M; Hosokawa S; Masubuchi Y; Suzuki T
Biochem Biophys Res Commun; 1993 Jun; 193(3):1262-8. PubMed ID: 8323546
[TBL] [Abstract][Full Text] [Related]
19. Neuronal cytochrome P450IID1 (debrisoquine/sparteine-type): potent inhibition of activity by (-)-cocaine and nucleotide sequence identity to human hepatic P450 gene CYP2D6.
Tyndale RF; Sunahara R; Inaba T; Kalow W; Gonzalez FJ; Niznik HB
Mol Pharmacol; 1991 Jul; 40(1):63-8. PubMed ID: 1857341
[TBL] [Abstract][Full Text] [Related]
20. Characterization of a human liver cytochrome P-450 involved in the oxidation of debrisoquine and other drugs by using antibodies raised to the analogous rat enzyme.
Distlerath LM; Guengerich FP
Proc Natl Acad Sci U S A; 1984 Dec; 81(23):7348-52. PubMed ID: 6594694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
